These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16353164)

  • 21. Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer's disease: a review with methodological considerations.
    Wimo A
    Drugs Aging; 2004; 21(5):279-95. PubMed ID: 15040756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Harmonisation of availability of drugs for Alzheimer's disease.
    Winblad B
    Lancet; 1999 Jul; 354(9174):257. PubMed ID: 10421337
    [No Abstract]   [Full Text] [Related]  

  • 23. Effectiveness and cost-effectiveness of the pharmacological treatment of Alzheimer's disease and vascular dementia.
    Versijpt J
    J Alzheimers Dis; 2014; 42 Suppl 3():S19-25. PubMed ID: 25061049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study notes huge costs associated with Alzheimer's disease.
    Levenson D
    Rep Med Guidel Outcomes Res; 2002 Feb; 13(4):7-9. PubMed ID: 12434776
    [No Abstract]   [Full Text] [Related]  

  • 25. Questions about donepezil.
    Elie LM; Cole MG
    CMAJ; 1998 Apr; 158(8):1014-5. PubMed ID: 9580729
    [No Abstract]   [Full Text] [Related]  

  • 26. Alzheimer's disease. Three-score years and then?
    Bryan J
    Health Serv J; 1998 Aug; 108(5619):suppl 4-5, 7-8. PubMed ID: 10185456
    [No Abstract]   [Full Text] [Related]  

  • 27. [A contribution to the current discussion on anti-dementia drugs in Germany].
    Jessen F; Maier W
    Nervenarzt; 2007 May; 78(5):491-2, 494, 496-7. PubMed ID: 17106726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.
    Rockwood K; Dai D; Mitnitski A
    Int J Geriatr Psychiatry; 2008 Feb; 23(2):207-14. PubMed ID: 17621382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term changes in ADAS-cog: what is clinically relevant for disease modifying trials in Alzheimer?
    Vellas B; Andrieu S; Cantet C; Dartigues JF; Gauthier S
    J Nutr Health Aging; 2007; 11(4):338-41. PubMed ID: 17653494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK.
    Ward A; Caro JJ; Getsios D; Ishak K; O'Brien J; Bullock R;
    Int J Geriatr Psychiatry; 2003 Aug; 18(8):740-7. PubMed ID: 12891643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease.
    Rockwood K; Fay S; Gorman M
    Int J Geriatr Psychiatry; 2010 Feb; 25(2):191-201. PubMed ID: 19548273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current Alzheimer's medications: effective treatment options, or expensive bottles of hope?
    Vann AS
    J Am Med Dir Assoc; 2013 Jul; 14(7):525-6. PubMed ID: 23664019
    [No Abstract]   [Full Text] [Related]  

  • 33. Drug treatment for Alzheimer's disease: the way forward.
    Maidment I; Fox C; Livingston G; Katona C
    Int J Geriatr Psychiatry; 2006 Jan; 21(1):6-8. PubMed ID: 16353163
    [No Abstract]   [Full Text] [Related]  

  • 34. Drugs for Alzheimer's disease. Guidelines for prescribing cholinesterase inhibitors in Australia are similar to those in UK.
    Noble JM
    BMJ; 2001 Nov; 323(7321):1128. PubMed ID: 11725756
    [No Abstract]   [Full Text] [Related]  

  • 35. Acetylcholinesterase inhibitors in Alzheimer's disease.
    McGleenon BM; Dynan KB; Passmore AP
    Br J Clin Pharmacol; 1999 Oct; 48(4):471-80. PubMed ID: 10583015
    [No Abstract]   [Full Text] [Related]  

  • 36. The stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer's disease.
    Wiig EH; Annas P; Basun H; Andreasen N; Lannfelt L; Zetterberg H; Blennow K; Minthon L
    Acta Neurol Scand; 2010 Mar; 121(3):186-93. PubMed ID: 19785641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences in Alzheimer disease clinical trial outcomes based on age of the participants.
    Schneider LS; Kennedy RE; Wang G; Cutter GR
    Neurology; 2015 Mar; 84(11):1121-7. PubMed ID: 25681452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease.
    Wesnes K; Edgar C; Andreasen N; Annas P; Basun H; Lannfelt L; Zetterberg H; Blennow K; Minthon L
    Acta Neurol Scand; 2010 Oct; 122(4):270-7. PubMed ID: 20047570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NICE guidelines unfair for Alzheimer's disease.
    Lowery K
    Br J Nurs; 2001 Nov 8-21; 10(20):1314. PubMed ID: 11873223
    [No Abstract]   [Full Text] [Related]  

  • 40. Cholinesterase inhibitors in late-stage Alzheimer's disease.
    Gauthier S
    Lancet Neurol; 2006 Jun; 5(6):468-9. PubMed ID: 16713915
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.